期刊文献+

熊果酸对t(8;21)白血病细胞kasumi-1的抗肿瘤作用机制的研究 被引量:3

Mechanism of Antitumor Effect of Usolic Acid on t( 8; 21) Leukemia Cell Kasumi-1
暂未订购
导出
摘要 本研究旨在探讨熊果酸对急性髓系白血病t(8;21)阳性细胞株kasumi-1细胞的抑制增殖、诱导凋亡机制。采用CCK-8法检测细胞增殖抑制,瑞氏染色法观察细胞凋亡形态,流式细胞术检测细胞凋亡率,实时荧光定量PCR法及Western blot法检测kasumi-1细胞内相关基因mRNA及蛋白的表达。结果表明,经熊果酸处理后的kasumi-1细胞的生长增殖受到抑制,出现凋亡形态学改变;在熊果酸2.5、5、10、20、50μmol/L浓度梯度以及在12,24,36,48,60,72 h时间梯度下,Annexin V阳性细胞比率随药物浓度的增加及作用时间的延长呈上升趋势;细胞内AML1-ETO、KIT、MYC、CCND1、BCL2、MDM2 mRNA的表达随作用时间的延长及用药浓度的增加而呈显著的下降趋势,而P53及BAX的mRNA表达逐渐增高;Western blot显示AML1-ETO、C-kit、C-MYC、BCL-2蛋白表达减低,而P53蛋白表达增高。结论:熊果酸呈浓度和时间依赖性抑制kasumi-1细胞的增殖并诱导其凋亡,从而发挥抗白血病的作用。这为t(8;21)白血病靶向治疗方案的选择提供理论依据。 This study was purposed to investigate the anti-tumor effect of ursolic Acid (UA) on t (8;21) leukemia cell line kasumi-1 and its possible mechanismisms. The kasumi-1 cells were treated with UA at different concentration for different duration of time. The growth inhibition of kasumi-1 treted with UA was detected by using CCK-8 test, and the morphological changes of kasumi-1 cells were observed by Wright's staining. Furthermore, the apoptosis rate of kasumi- 1 was examined by flow cytometry. Lastly, the expression of AML1-ETO, KIT, MYC, CCND1, BCL-2, P53, BAX, MDM2 and protein were detected by using real-time quantitative PCR and Western blot respectively. The results showed that the UA obviously inhibited the growth of kasumi-1 cells in dose- and time-dependent manners. The apototic morphological changes of cells were presented when kasumi-1 cells were treated with UA for 48 hours. The apoptotic rate of kasumi-1 cells increased in a dose- and time-dependent ways, and the mRNA levels of AML1-ETO, KIT, MYC, CCND1, BCL2, MDM2 decreased in kasumi-1 cells treated with UA, as well as the protein levels. Meanwhile, UA upregulated the mRNA and protein levels of P53 in the same manner. It is concluded that UA can exert its anti-tumor effect by inhibiting the proliferation and inducing the apoptosis of kasumi-1 cells in a dose-and time-dependent manners, that may provide the clues for a new targeting therapy to t(8 ;21 ) leukemia.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2014年第3期687-691,共5页 Journal of Experimental Hematology
关键词 熊果酸 KASUMI-1 增殖抑制 诱导凋亡 ursolic acid kasumi-1 inhibition of proliferation induction of apoptosis
  • 相关文献

参考文献7

  • 1Telfer JC, Rothenberg EV. Expression and function of a stem cell promoter for the murine CBF alpha 2 gene: distinct roles and regulation in natural killer and T cell development. Developmental Biology, 2001 ; 229(2) :363 -382.
  • 2Zhou GB, Kang H, Wang L, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t (8;21) leukemia in vitro and in vivo. Blood,2007;109(8) :41 - 50.
  • 3王静.熊果酸抗肿瘤作用研究进展[J].临床合理用药杂志,2010,3(6):120-121. 被引量:6
  • 4Zhang J, Hug BA, Huang EY, et al. Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell Biol,2001 ; 21 ( 1 ) : 156 - 163.
  • 5Lutterbach B, Westendorf J J, Linggi B, et al. A target of t ( 8 ;21 ) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol, 1998; 18(12) :7176-7184.
  • 6Wang I, Hoshino T, Redner RL, et al. ETO, fusion partner in t [8; 21 ] acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Nail Acad Sci USA, 1998; 95 (18) :10860 -10865.
  • 7Yarden Y, Kuang WJ,Yang-Feng T,et al. Human proto-oncogene C-Kit:a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J, 1987 ; 6 ( 11 ) :3341 - 3351.

二级参考文献8

共引文献5

同被引文献59

  • 1陈腾,施靖华,赵荣华,李莉.胃癌患者手术前后淋巴细胞表型CD49 b、CD49 d的变化及其临床意义[J].临床和实验医学杂志,2006,5(5):457-458. 被引量:1
  • 2Licht JD.AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21)AML.Oncogene,2001;20(40):5660-5679.
  • 3Taipale M,Kaminen N,Nopola-Hemmi J,et al.A candidate gene for developmental dyslexia encodes a nuclear tetratricopeptide repeat domain protein dynamically regulated in brain.Proc Natl Acad Sci USA,2003;100(20):11553-11558.
  • 4Muller AM,Duque J,Shizuru JA,et al.Complementing mutations in core binding factor leukemias:from mouse models to clinical applications.Oncogene,2008;27(44):5759-5773.
  • 5Sun XJ,Wang Z,Wang L,et al.A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.Nature,2013;500(7460):93-97.
  • 6Yan M,Kanbe E,Peterson LF,et al.A previously unidentified alternatively spliced isoform of t(8;21)transcript promotes leukemogenesis.Nat Med,2006;12(8):945-949.
  • 7Marcucci G,Mrozek K,Ruppert AS,et al.Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21)differ from those of patients with inv(16):a Cancer and Leukemia Group B study.J Clin Oncol,2005;23(24):5705-5717.
  • 8Zhang L,Li Q,Li W,et al.Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).Int J Hematol,2013;97(6):786-792.
  • 9Zhu HH,Zhang XH,Qin YZ,et al.MRD-directed risk stratification treatment may improve outcomes of t(8;21)AML in the first complete remission:results from the AML05 multicenter trial.Blood,2013;121(20):4056-4062.
  • 10Klisovic MI,Maghraby EA,Parthun MR,et al.Depsipeptide(FR901228)promotes histone acetylation,gene transcription,apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.Leukemia,2003;17(2):350-358.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部